In further support, BRAFV600E inhibitor treatments have been associated with dendritic cell maturation, increased expression of co-stimulatory molecules including CD40L, production of IFNγ, TNFα and IL-12, and moderate enhancement of circulating tumor antigen-reactive CD8+ T cells [76, 77–78]. The gene discussed is IFNG; the disease is neoplasm.